News

Newly diagnosed multiple myeloma patients who use Revlimid (lenalidomide) as a maintenance therapy after a stem cell transplant live significantly longer than those receiving a placebo…

PharmaMar is launching a clinical trial to explore its investigational therapy Aplidin (plitidepsin) in a quadruple combination treatment for multiple myeloma. The four compounds involved…

NantKwest’s Vax-DC/MM cell therapy has induced a partial or complete response in 42 percent of relapsed or refractory multiple myeloma (MM) and lymphoma patients in a…

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone…

Sutro Biopharma‘s STRO-001 eliminates or significantly slows the growth of non-Hodgkin lymphoma and multiple myeloma tumors, studies in mice indicate. Sutro expects the results to support…

Revlimid (lenalidomide) therapy maintenance has been shown to delay disease progression and extend survival in newly diagnosed multiple myeloma (NDMM) patients who receive a transplant…

Stem cell transplants derived from patients’ own bone marrow are a safe and effective treatment for those with multiple myeloma who fail to respond to first-line…

The Cancer Support Community (CSC), a nonprofit advocacy organization, recently released a research report about the emotional, social, and financial burdens on cancer patients. The…

Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with  Velcade (bortezomib) with dexamethasone — information that …

Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of…